STOP-HAE: A Phase 3 Study of ADX-324 in HAE

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2

In brief

This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.

Key facts

Study ID
NCT06960213
Run by
ADARx Pharmaceuticals, Inc.
People needed
90
Starts
2025-08-28
Expected to finish
2027-12-31
Last updated by the study team
2026-06-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.